A Clinical Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Head & Neck Cancers
Latest Information Update: 19 Aug 2025
At a glance
- Drugs CD 001 (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
Most Recent Events
- 03 Aug 2025 Planned initiation date changed from 1 Aug 2025 to 10 Aug 2025.
- 30 Jul 2025 New trial record